Vinorelbine Tartrate
Catalog No.S4269
Molecular Weight(MW): 1079.11
Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.
5 Customer Reviews
-
Activity of vinorelbine in NSCLC cell lines in cell viability assay. Activity of vinorelbine NCI-H23, NCI-H460, and NCC44 cell lines in a Cell Titer Glo cell viability assay. Cells were treated with increasing drug concentrations from 0-10000 nM. The data are plotted as the mean % of control cells against the corresponding drug concentration.
Cynthia Bernia from McGill University. Vinorelbine Tartrate purchased from Selleck.
JQ1 and chemotherapeutics (vinorelbine, docetaxel, cisplatin and carboplatin) cooperate to induce apoptosis. MDA-MB-231 and HS578T were exposed to drugs alone and in combination with JQ1, at the indicated doses. Apoptosis was examined after 72 hours of treatment by flow cytometry using Annexin V/ PI staining as previously described.
Mol Cancer Ther, 2016, 15(8):1823-33.. Vinorelbine Tartrate purchased from Selleck.
-
PyMT:Irs-2−/− cells transfected with empty vector (Irs2−/−) or IRS2 (Irs2−/−:IRS2) were treated with DMSO, 1 μm nocodazole, 20 nm vinblastine (Vin), or 20 nm vinorelbine (Vino) for 1 h and then stimulated with IGF-1 (10 ng/ml) for 15 min.
J Biol Chem, 2017, 292(19):7806-7816. Vinorelbine Tartrate purchased from Selleck.
Combination drug treatment increased multinucleated giant cells via spindle microtubule alteration and cell cycle arrest. Immunofluorescent staining of BT-20 cell line after treatment with vinorelbine (NVB) or vinorelbine in combination with 5 μM of either ME0328 (NVB + ME) or olaparib (NVB + Olaparib) for 24 h. Cells were stained with Dapi for DNA (blue). α-tubulin for microtubules (green) and the merge with a 100× objective. Abundant multinucleated giant cells observed in cells treated with NVB + ME and NVB + Olaparib comparing with NVB alone.
Breast Cancer Res Treat, 2018, 172(1):23-32. Vinorelbine Tartrate purchased from Selleck.
-
Dose-response curves of vinorelbine. Cells and microtissues are treated with increasing doses of the anti-mitotic microtubuli inhibitor vinorelbine for 24 and 48 h. The response of 2D cultivated cells compared to microtissues was determined measuring intra-cellular ATP, LDH release and cell viability (*p < 0.05; n = 3 for ATP assay; n = 3–7 for LDH assay; n = 3–4 for flow cytometry)
J Cancer Res Clin Oncol, 2016, 142(9):1955-66. Vinorelbine Tartrate purchased from Selleck.
Purity & Quality Control
Choose Selective Microtubule Associated Inhibitors
Biological Activity
| Description | Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin. | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Features | A semi-synthetic vinca alkaloid as an anti-mitotic chemotherapy drug. | |||||||||||||||||||||||||||||||||||||
| Targets |
|
|||||||||||||||||||||||||||||||||||||
| In vitro |
Vinorelbine inhibits microtubule assembly by inducing tubulin aggregation into spirals and paracrystals. [1] Vinorelbine shows potent antiproliferative activity against a series of tumor cells, including human melanoma, non-small-cell lung cancer, breast cancer, etc. [2][3][4] |
|||||||||||||||||||||||||||||||||||||
| Cell Data |
|
|||||||||||||||||||||||||||||||||||||
| In vivo | In vivo, Vinorelbine also shows antitumour activity against a series of subcutaneously-implanted human tumour xenografts. [5] |
Protocol
| Animal Research:[5] |
+ Expand
|
|---|
Solubility (25°C)
| In vitro | DMSO | 100 mg/mL (92.66 mM) |
|---|---|---|
| Water | 100 mg/mL warmed (92.66 mM) | |
| Ethanol | 100 mg/mL warmed (92.66 mM) |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 1079.11 |
|---|---|
| Formula | C45H54N4O8.2C4H6O6 |
| CAS No. | 125317-39-7 |
| Storage | powder |
| in solvent | |
| Synonyms | N/A |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03770299 | Not yet recruiting | Non-Small Cell Lung Cancer|Non-Small-Cell Lung Carcinoma|Circulating Tumor DNA | Bristol-Myers Squibb | March 15 2019 | Phase 2 |
| NCT03811418 | Not yet recruiting | Advanced Breast Cancer|HER2-positive Breast Cancer | iOMEDICO AG|Arbeitsgemeinschaft fur Internistische Onkologie|Amgen | March 1 2019 | Phase 3 |
| NCT03770299 | Not yet recruiting | Non-Small Cell Lung Cancer|Non-Small-Cell Lung Carcinoma|Circulating Tumor DNA | Bristol-Myers Squibb | March 15 2019 | Phase 2 |
| NCT03811418 | Not yet recruiting | Advanced Breast Cancer|HER2-positive Breast Cancer | iOMEDICO AG|Arbeitsgemeinschaft fur Internistische Onkologie|Amgen | March 1 2019 | Phase 3 |
| NCT03839823 | Not yet recruiting | Breast Cancer | Novartis Pharmaceuticals|Novartis | February 28 2019 | Phase 2 |
| NCT03839823 | Not yet recruiting | Breast Cancer | Novartis Pharmaceuticals|Novartis | February 28 2019 | Phase 2 |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
